CRES.Y heads into its May 7 earnings call with a clear near-term signal: the company's Non-Executive Vice Chairman has been buying shares on the open market, picking up roughly 17,800 shares across three transactions this week at around $11.20–11.25 apiece, totalling just over $200,000. The purchases, filed with the SEC on April 25, are a direct vote of confidence at a price level that sits 7% below last month's close.
The insider buying matters here because it comes against a backdrop of a sharply resetting short position. Short interest surged 33% week-on-week to roughly 244,000 shares — a striking headline number — but it follows an even larger collapse in February and March, when shorts ran above 980,000 shares before falling nearly 80% through mid-April. The current level is a fraction of where shorts were positioned six weeks ago. The rebuilding this week looks more like residual repositioning than a fresh conviction bet. ORTEX puts the short score at 32.4, edging up slightly through the week but still in the lower third of the scale — not a number that signals serious short-side pressure.
The lending market is consistent with that reading. Availability is ample — borrow utilisation is just 15%, well below the 52-week high of nearly 90% reached earlier in the cycle. Cost to borrow has actually eased over the past seven days, falling around 20% to 1.31% annualised. That combination — low cost, loose availability — tells you there is no meaningful queue to borrow shares. Whatever shorts are doing this week, they are not squeezed.
Options positioning leans slightly more cautious but is nowhere near alarming. The put/call ratio edged up to 0.53 on April 28, fractionally above its 20-day average of 0.51 and less than 0.2 standard deviations from the mean. The year's high was 1.74; the current reading is far closer to the low end of the range. Call volume is still dominating — options traders, on balance, are positioned more for upside than downside. The dividend factor score ranks in the 87th percentile, a residual reflection of the company's long history of capital returns to shareholders in Argentina, even if no cash dividend has been paid in recent years.
Analyst data is stale — the most recent price target of $14.93 was set in February 2026, offering a rough 33% implied upside to the current price of $11.24. Given the gap in time and the company's exposure to Argentine macro dynamics, that figure is informational rather than actionable. The last confirmed earnings reaction, in February, saw a 2.2% one-day gain followed by a modest 1% five-day drift — a low-volatility template heading into the May 7 print.
Institutional ownership is concentrated. Inversiones Financieras Del Sur holds 20% of shares; Eduardo Sergio Elsztain directly controls another 12.5%. Alejandro Gustavo Elsztain — the Non-Executive Vice Chairman doing the buying this week — reported adding over 12 million shares in Q1, suggesting the insider transactions this week are part of a sustained accumulation rather than a one-off. The tightest lens on this name going into earnings is therefore not shorts or options but whether the Elsztain family's continued buying converges with a stable macro environment for Argentine agri-business — and whether the May 7 results frame either as validated.
See the live data behind this article on ORTEX.
Open CRES.Y on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
